Survey on Anemia Therapy With ESAs Medication in Chronic Kidney Disease Patients Not on Dialysis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 196
- 试验地点
- 7
- 主要终点
- Percentage of Participants by ESA Types at Baseline
研究概览
简要总结
This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis participant population in Israel. Participating physicians will be requested to interview eligible participants with CKD not on dialysis and to complete for them a satisfaction survey for anemia treatment. The survey will be completed twice, once at study start and once at six months' follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult participants with CKD Stage 3-5
- •Treated with ESAs
- •Participant is speaking the same language as the investigator interviewer
排除标准
- •Past or current treatment with dialysis
研究组 & 干预措施
Chronic Renal Anemia Participants
Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
干预措施: ESA (Drug)
Chronic Renal Anemia Participants
Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
干预措施: Satisfaction Survey Questionnaire (Other)
结局指标
主要结局
Percentage of Participants by ESA Types at Baseline
时间窗: Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Percentage of Participants by Frequency and Types of ESA Used at Baseline
时间窗: Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Percentage of Participants by ESA Types at Month 6
时间窗: Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Percentage of Participants by Frequency of ESA Use at Baseline
时间窗: Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Percentage of Participants by Frequency of ESA Use at Month 6
时间窗: Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Percentage of Participants by Frequency and Types of ESA Used at Month 6
时间窗: Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
次要结局
- Percentage of Participants by Different Injection Administration Modes(Baseline, Month 6)
- Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type(Baseline, Month 6)
- Percentage of Participants With Interest in Learning to Inject Independently(Baseline, Month 6)
- Percentage of Participants by Preferred Treatment Frequency(Baseline, Month 6)
- Percentage of Participants by Different CKD Stages(Baseline, Month 6)
- Percentage of Participants by Need for Improvement in Treatment Frequency(Baseline, Month 6)
- Percentage of Participants by Convenience of Syringe Usage(Baseline, Month 6)
- Percentage of Participants by Injection Site Pain by ESA Type(Baseline, Month 6)
- Percentage of Participants by Convenience of Syringe Usage by ESA Type(Baseline, Month 6)
- Percentage of Participants by Preferred Treatment Frequency by ESA Type(Baseline, Month 6)
- Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency(Baseline, Month 6)
- Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements(Baseline, Month 6)
- Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types(Baseline, Month 6)
- Percentage of Participants by Injection Site Pain(Baseline, Month 6)